Results about: chemotherapy
In EMBO Molecular Medicine, IRB Barcelona scientists report a technique based on a combination of CRISPR/Cas9 genome editing and patient-derived tumour organoids that allows the study of cell heterogeneity in human tumours.
The novel approach was used to examine the behaviour of colorectal cancer stem cells by tracing specific marker genes.
These comprise a small group of passive stem cells—quiescent—that are activated when needed and have the capacity to produce any kind of intestinal cell.
Quiescent cells are relevant for tissue regeneration and for their participation in tumour development.
The molecules synthesized by Ernest Giralt’s lab at IRB Barcelona bind a key protein in cancer that has received little attention as a therapeutic target.
The long-term goal is to provide a new chemotherapy treatment.